Celestia S. Higano Discusses Sexual Health Services for Prostate Cancer Survivors

Video

Celestia S. Higano, MD, of the Seattle Cancer Care Alliance, discusses sexual health services that are available to survivors of prostate cancer.

Celestia S. Higano, MD, of the Seattle Cancer Care Alliance, discusses sexual health services that are available to survivors of prostate cancer.

Higano mentions that while many men face sexual health issues such as erectile dysfunction after receiving radiation or surgery for prostate cancer, there are not enough sexual health clinicians to help them cope. She also mentions the increasing availability of online sexual health resources for survivors, which need further study, but may prove to be another useful option to provide support to this population.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman with blonde hair wearing a denim jacket in front of a blue background
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Related Content
Blue image of kidneys with renal tubules highlighted in red

Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

Tim Cortese
February 15th 2025
Article

Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Graphic of care providers, patients, and families conversing near large computers and health charts

Digital Health Tool Helps Patients With Prostate Cancer During Consultations

Bridget Hoyt
February 14th 2025
Article

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.

Key Advances in Cancer Survivorship Toxicity Management

Key Advances in Cancer Survivorship Toxicity Management

Lindsay Fischer
July 15th 2022
Podcast

In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.

Rendering of prostate cancer cells

Clinical Practice Gaps Persist in Biomarker Testing for mCRPC Management

Darlene Dobkowski, MA
February 13th 2025
Article

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is needed to address these gaps.

Rendering of a bladder and prostate, surrounded by images of cancerous cells

Talazoparib-Enzalutamide Combo Increases OS in mCRPC

Jordyn Sava
February 13th 2025
Article

Patients with HRR-deficient metastatic castration-resistant prostate cancer saw a 14-month boost in OS and a 38% lower risk of death with talazoparib plus enzalutamide.